Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Comi

Showing results (571-580 of 586) with videos related to

Pageof 59
Sort By:
Genes and Immunity|May 14, 2010
Progranulin gene variability increases the risk for primary progressive multiple sclerosis in malesC Fenoglio, D Scalabrini, F Esposito, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 29, 2013
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 casesA Ghezzi, P Annovazzi, E Cocco, et al.
Annals of Neurology|October 23, 2009
Real-life impact of early interferon beta therapy in relapsing multiple sclerosisM Trojano, F Pellegrini, D Paolicelli, et al.
Neurology|March 23, 2007
Phenotypic clustering of lamin A/C mutations in neuromuscular patientsS Benedetti, I Menditto, M Degano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 15, 2011
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological SocietyA Ghezzi, L M E Grimaldi, M G Marrosu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 21, 2010
Three years of experience: the Italian registry and safety data updateG L Mancardi, G Tedeschi, M P Amato, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
The Pharmacogenomics Journal|March 23, 2016
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association studyS Mahurkar, M Moldovan, V Suppiah, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
The pharmacovigilance program on natalizumab in Italy: 2 years of experienceG Tedeschi, M P Amato, R D'Alessandro, et al.
Journal of the Neurological Sciences|July 21, 2009
Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatmentM Trojano, F Pellegrini, D Paolicelli, et al.
Pageof 59

Showing results (571-580 of 586) with videos related to

Sort By:
Pageof 59
Genes and Immunity|May 14, 2010
Progranulin gene variability increases the risk for primary progressive multiple sclerosis in malesC Fenoglio, D Scalabrini, F Esposito, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 29, 2013
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of 462 casesA Ghezzi, P Annovazzi, E Cocco, et al.
Annals of Neurology|October 23, 2009
Real-life impact of early interferon beta therapy in relapsing multiple sclerosisM Trojano, F Pellegrini, D Paolicelli, et al.
Neurology|March 23, 2007
Phenotypic clustering of lamin A/C mutations in neuromuscular patientsS Benedetti, I Menditto, M Degano, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|January 15, 2011
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group--Italian Neurological SocietyA Ghezzi, L M E Grimaldi, M G Marrosu, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|July 21, 2010
Three years of experience: the Italian registry and safety data updateG L Mancardi, G Tedeschi, M P Amato, et al.
The Lancet. Neurology|September 5, 2009
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre studyPaul O'Connor, Massimo Filippi, Barry Arnason, et al.
The Pharmacogenomics Journal|March 23, 2016
Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association studyS Mahurkar, M Moldovan, V Suppiah, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 3, 2009
The pharmacovigilance program on natalizumab in Italy: 2 years of experienceG Tedeschi, M P Amato, R D'Alessandro, et al.
Journal of the Neurological Sciences|July 21, 2009
Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatmentM Trojano, F Pellegrini, D Paolicelli, et al.
Pageof 59